Drug Profile

AD 35

Alternative Names: AD-35

Latest Information Update: 23 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zhejiang Hisun Pharmaceutical
Developer Medpace; Zhejiang Hisun Pharmaceutical
Class Antidementias; Cyclopropanes; Dioxoles; Isoindoles; Neuroprotectants; Piperidines; Pyridines; Small molecules; Spiro compounds
Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Astrocyte inhibitors; Interleukin 1 alpha inhibitors; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Mar 2021 AD 35 is still in phase II trials for Alzheimer's disease in USA and China (PO)
01 Dec 2018 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in China (PO) (NCT03790982)
04 Sep 2018 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com